Context: Fibroblast growth factor (FGF)19 and FGF21 are secreted by the intestine and liver in response to macronutrient intake. Intestinal resection and reconstruction via bariatric surgery may alter their regulation.
F ibroblast growth factor (FGF)19 (the human ortholog of FGF15 in the mouse) and FGF21 are involved in the regulation of energy, glucose, and lipid metabolism (1) . FGF21 is also involved in regulating sweet taste preference and dietary macronutrient selection (2) (3) (4) . FGF19 is made in the ileum and is secreted into the bloodstream in response to macronutrient ingestion and intraluminal bile acids (1, (5) (6) (7) (8) (9) . FGF21 is predominantly made in the liver (1) and is secreted in response to glucose ingestion, whereas protein and fat ingestion inhibit its release (7, 10, 11) .
The regulation of FGF19 and FGF21 secretion by macronutrient ingestion suggests that Roux-en-Y gastric bypass (RYGB) surgery could have profound effects on their postprandial metabolism, because RYGB alters postprandial bile acid metabolism and causes rapid delivery of ingested nutrients, particularly glucose, to the upper intestine where it is absorbed and delivered to the liver (12) (13) (14) . However, the effect of RYGB on FGF19 and FGF21 metabolism after mixed meal ingestion is unclear because of conflicting results from different studies (15) (16) (17) (18) (19) , which found that postprandial plasma FGF19 concentration did not change (17, 18) or increased (15, (17) (18) (19) and that postprandial plasma FGF21 concentration did not change (16) or decreased (17) after RYGB. The reasons for these discrepancies are unclear but could be related to differences in meal macronutrient composition as well as the rate of digestion and absorption of ingested macronutrients among studies.
The purpose of the present study was to evaluate the effect of gastrointestinal reconstruction and weight loss induced by RYGB on postprandial glucose kinetics, and FGF19 and FGF21 metabolism. We hypothesized that the postprandial increase in proximal intestinal glucose absorption after RYGB-induced weight loss would cause a greater increase in the secretion of FGF19 and FGF21 into the circulation than the same weight loss induced by laparoscopic adjustable gastric banding (LAGB). Accordingly, we evaluated the effect of mixed meal ingestion on mealderived glucose kinetics and plasma FGF19 and FGF21 concentrations in subjects with obesity before and after matched 20% weight loss induced by either RYGB or LAGB. Postprandial delivery of ingested glucose to the liver and systemic circulation was evaluated by using a dual (oral and intravenous) stable isotopically labeled glucose tracer administration (13) . We also evaluated the effect of constant intravenous glucose infusion, by using the hyperinsulinemic-euglycemic clamp procedure (HECP), on plasma FGF19 and FGF21 concentrations in the same subjects to distinguish the effects of orally ingested from intravenously infused glucose on FGF metabolism.
Methods

Study subjects
Twenty-eight men and women who underwent RYGB (n = 16, 2 men and 14 women; age, 43.7 6 1.8 years; body mass index, 45.5 6 1.4 kg/m 2 ) or LAGB (n = 12, 1 man and 11 women; age, 47.7 6 3.8 years; body mass index, 46.6 6 2.3 kg/m 2 ) procedures at Barnes-Jewish Hospital in St. Louis, MO, participated in this study, which was approved by the Washington University School of Medicine Institutional Review Board. All subjects gave written, informed consent before enrolling in the study. Potential study subjects who had diabetes, previous intestinal surgery, or a history of inflammatory intestinal disease were excluded. Glucose kinetics after mixed meal ingestion and during the HECP before and after surgery-induced weight loss were previously reported in some of the subjects (13) . In the RYGB group, one participant completed the mixed meal metabolic study but not the HECP; in the LAGB group, one participant completed the HECP but not the mixed meal metabolic study.
Study design and experimental procedures
Body composition
Body fat mass and fat free mass (FFM) were determined by using dual energy X-ray absorptiometry (Lunar iDXA; GE Healthcare Lunar, Madison, WI). Intra-abdominal adipose tissue volume and intrahepatic triglyceride content were determined by using magnetic resonance imaging and spectroscopy, respectively (1.5-T superconducting magnet; Siemens, Iselin, NJ) (20, 21) .
Mixed meal metabolic study
Subjects were admitted to the Washington University School of Medicine Clinical Research Unit in the afternoon before the study and consumed a standard evening meal containing 12 kcal/kg FFM (50% carbohydrate, 30% fat, 20% protein). The following morning, after subjects fasted for ;12 hours overnight, a catheter was inserted into a forearm vein for stable isotopically labeled glucose infusion, and a second catheter was placed into a radial artery to obtain blood samples. At 6:00 AM, a primed, continuous infusion of [6, H 2 ]glucose (priming dose, 22 mmol/kg; infusion rate, 0.22 mmol/kg/min) was started and maintained until the end of the study. At 9:30 AM, subjects ingested a liquid meal (containing 46 g of glucose mixed with 0.9 g of [U- 13 C]glucose, 9 g of fat, and 9 g of protein), which was provided in seven equal aliquots every 5 minutes during 30 minutes. Blood samples were obtained before starting the tracer infusion, every 10 minutes for 30 minutes before consuming the meal, and every 15 minutes for the first hour and then every 20 minutes for the subsequent 5 hours after starting the meal to determine plasma glucose, insulin, FGF19, and FGF21 concentrations and ingested glucose rate of appearance (Ra) into the systemic circulation and endogenous glucose production (EGP) rate.
HECP
Subjects were admitted to the Clinical Research Unit and consumed a standard evening meal containing 12 kcal/kg FFM (50% carbohydrate, 30% fat, 20% protein). The following morning, after an overnight fast, a catheter was inserted into a forearm vein for infusion of insulin, dextrose, and stable isotopically labeled glucose, and a second catheter was inserted into a radial artery to obtain blood samples. At 6:00 AM, a primed, continuous infusion of [6, H 2 ]glucose (priming dose, 22 mmol/kg; infusion rate, 0.22 mmol/kg/min) was started and maintained for 3.5 hours. At 9:30 AM, an infusion of insulin was initiated with two consecutive 5-minute priming doses (200 mU/m 2 body surface area/min followed by 100 mU/m 2 body surface area/min) followed by constant rate infusion (50 mU/m 2 body surface area/min) for 230 minutes. Euglycemia (plasma glucose ;100 mg/dL) was maintained by variable rate infusion of a 20% dextrose solution enriched to 2.5% with [6,6-2 H 2 ]glucose. Blood samples were obtained immediately before starting the tracer infusion and every 10 minutes during the final 30 minutes of the basal period and the clamp procedure to determine plasma glucose, insulin, FGF19, and FGF21 concentrations and glucose kinetics.
Bariatric surgery and weight management after surgery
After baseline testing was completed, RYGB and LAGB were performed by using standard techniques as previously described (13) . After surgery, subjects participated in a supervised dietary weight loss program designed to achieve a 20% weight loss within 4 to 6 months. Once this targeted amount of weight loss was achieved, subjects were prescribed a weight maintenance diet to maintain a stable body weight (,2% change) for at least 2 weeks before the studies conducted before surgery were repeated.
Sample and data analyses
Plasma glucose concentration was determined by using an automated glucose analyzer (YSI 2300 STAT plus; Yellow Spring Instrument). Enzyme-linked immunosorbent assays were used to measure the concentrations of insulin (EMD Millipore, St. Charles, MO) as well as FGF19 and FGF21 (R&D Systems, Minneapolis, MN) in plasma. Plasma glucose tracer-to-tracee ratios were determined by using gas chromatography-mass spectrometry (Hewlett-Packard MSD 5973 system with capillary column) as previously described (22) . Postprandial glucose, insulin, FGF19, and FGF21 areas under the curve (AUCs), basal and postprandial EGP rates, ingested glucose Ra into plasma, and insulin-stimulated glucose rate of disappearance from plasma during the HECP were calculated as previously described (13) .
Statistical analyses
All data sets were tested for normality by using the Kolmogorov-Smirnov test, and skewed data sets were log transformed for further analysis. Two-way [group (LAGB vs RYGB) 3 time (before and after surgery)] repeated measures analysis of variance was used to evaluate the effect of surgeryinduced weight loss on body composition and metabolic variables that were measured at a single time point. Three-way [group (LAGB vs RYGB) 3 time (before and after surgery) 3 condition (basal vs clamp or basal vs postprandial)] repeated measures analysis of variance was used to evaluate the effects of RYGB and LAGB surgery on variables that were assessed both during basal conditions and after mixed meal ingestion or during the HECP. Significant group 3 time or group 3 time 3 condition interactions were followed by a Tukey post hoc procedure to identify significant differences. A P value of # 0.05 was considered statistically significant. Data are presented as mean 6 SEM (normally distributed data) or median (quartiles; skewed data sets). Statistical analyses were conducted by using SPSS version 22 for Windows (IBM, Armonk, NY).
Results
Body composition
Surgery-induced weight loss decreased total body fat and FFMs, intra-abdominal adipose tissue volume, and intrahepatic triglyceride content in both the LAGB and RYGB groups, without any differences between groups (Table 1) .
Metabolic response to mixed meal ingestion
Fasting plasma glucose and insulin concentrations and postprandial glucose and insulin AUCs decreased to a similar extent in the two surgery groups (Table 2 ). Weight loss induced by RYGB caused an earlier and greater postprandial peak increase in plasma glucose and insulin concentrations and ingested glucose Ra in plasma than weight loss induced by LAGB (Fig. 1) . Neither RYGB nor LAGB affected the early postprandial suppression of EGP rate, but RYGB caused a faster subsequent return of EGP to basal values than did LAGB. Mean basal plasma FGF19 concentration was greater after than before weight loss in both the RYGB and LAGB groups, whereas mean basal plasma FGF21 concentration was not different before and after weight loss induced by either LAGB or RYGB (Table 2) . Both LAGB and RYGB increased total postprandial plasma FGF19 expressed as AUC, without a difference in AUC values between surgical groups ( Fig. 1; Table 2 ). However, RYGB caused an earlier peak increase in plasma FGF19 concentration than LAGB (1.9 6 0.1 hours vs 3.4 6 0.3 hours; P , 0.05). In contrast, postprandial plasma FGF21 AUC decreased after LAGB, but markedly increased after RYGB with a significant difference between surgical groups ( Fig. 1 ; Table 2 ).
Plasma FGF19 and FGF21 concentrations during the HECP
Weight loss caused an ;60% increase in insulinstimulated glucose disposal during the HECP in both the LAGB and RYGB groups without a difference between groups (Fig. 2) . Glucose and insulin infusion during the HECP did not affect plasma FGF19 concentration before or after surgery-induced weight loss in either group. In contrast, plasma FGF21 concentration nearly doubled during glucose and insulin infusion during the HECP before surgery and increased about threefold after surgery-induced weight loss, with no difference between groups (Fig. 2) .
Discussion
The FGF family consists of 22 members that have a wide range of functions. Two members of the FGF family, FGF19 and FGF21, are secreted into the bloodstream and have beneficial effects on glucose metabolism by enhancing muscle glucose uptake, regulating hepatic gluconeogenesis and glycolysis, and increasing pancreatic b-cell insulin content and secretion (23, 24) . Our data demonstrate that matched 20% weight loss induced by both LAGB and RYGB increased postprandial plasma FGF19 concentrations without a difference in total FGF19 AUC values between groups. In contrast, weight loss induced by RYGB, but not LAGB, caused a marked increase in postprandial plasma FGF21 concentrations. The peak increase in postprandial plasma FGF21 concentrations occurred 2 hours after the peak increase in the delivery of ingested glucose into the systemic circulation. In contrast, intravenous glucose infusion during the HECP did not affect plasma FGF19, but doubled plasma FGF21 concentrations without a difference in FGF21 values between surgery groups. These data demonstrate that the gastrointestinal alteration of RYGB has a unique effect on FGF19 and FGF21 responses to mixed meal ingestion, but not FGF19 and FGF21 responses to constant rate intravenous glucose infusion. Accordingly, these results underscore the importance of the delivery of ingested macronutrients into the gastrointestinal tract in regulating postprandial FGF19 and FGF21 metabolism.
Our data provide insights into the mechanism responsible for the effect of RYGB surgery on postprandial FGF21 metabolism. Approximately 20% of ingested glucose is cleared and metabolized by the liver; the remainder is delivered into the systemic circulation (25) . By using a dual (oral and intravenous) stable isotopically labeled tracer mixed meal method, we were able to determine ingested glucose Ra into the systemic circulation, which provides an index of the delivery of ingested glucose to the liver. Our data suggest the earlier and greater increase in postprandial FGF21 after RYGB, than after LAGB, is due to a more rapid delivery and absorption of ingested glucose to the liver. Glucose delivered to the liver activates carbohydrate response element binding protein, and in turn it increases hepatic FGF21 production (26) . In contrast, the increase in plasma FGF21 during the HECP was the same after LAGB and RYGB, presumably because the increases in glucose delivery to the liver were the same in both surgery groups.
The reason for the increase in postprandial plasma FGF19 concentrations after weight loss induced by both LAGB and RYGB surgeries is not clear. The shift toward an earlier peak in plasma FGF19 after RYGB than LAGB surgery suggests that earlier delivery of ingested macronutrients to the small intestine is involved in FGF19 secretion. Although glucose ingestion alone causes an increase in plasma FGF19 (5), it is likely that the effect of rapid intestinal delivery of ingested glucose and other meal macronutrients on postprandial bile acid metabolism also contributed to the early postprandial increase in FGF19 observed after RYGB surgery in our study participants. The ingestion of a meal stimulates gallbladder contraction and secretion of bile acids into the Data are means 6 standard error of the mean or median (quartiles) for normally distributed and skewed data sets, respectively. a P , 0.05 compared with value before surgery.
small intestine, with subsequent increase in plasma bile acid concentrations (27, 28) . Bile acids are potent ligands for the FXR receptor, and activation of ileal FXR stimulates FGF19 gene expression and production (29) . RYGB surgery causes a marked increase in postprandial plasma bile acid concentrations (19, 30) , which occurs before the increase in plasma FGF19 (31) . The absence of an effect of glucose infusion during the HECP on plasma FGF19 concentrations in our subjects underscores the importance of the gastrointestinal tract and bile acid metabolism on FGF19 secretion. The physiological importance of the observed increase in plasma FGF21 on postprandial glucose metabolism after RYGB surgery is not clear. FGF21 affects glucose disposal and EGP, but postprandial plasma FGF21 concentrations began to increase as plasma glucose and insulin began to decline, and plasma FGF21 concentrations peaked about 2 hours after the peak in plasma glucose and insulin concentrations. Therefore, these data do not support an important role for FGF21 in regulating postprandial glucose metabolism after RYGB.
Weight loss induced by RYGB has profound effects on macronutrient selection. People who have had RYGB surgery decrease the proportion of their daily energy intake from sweetened beverages and foods more than those who have had vertical banded gastroplasty (32) . Additionally, we have found that RYGB, but not LAGB, rapidly shifts sweetness palatability from pleasant to unpleasant when repetitively tasting sucrose (33) . The mechanism responsible for this alteration in food likely involves gastrointestinal-brain cross-talk. Data from studies conducted in rodent models have shown that increased FGF21 produced by the liver circulates to the brain and acts on the paraventricular nucleus of the hypothalamus to suppress sugar intake (2, 34) . The results from the present study support the possibility that the increases in both basal and postprandial plasma FGF21 concentrations after RYGB are involved in Figure 1 . Plasma glucose, insulin, FGF19, and FGF21 concentrations, ingested glucose rate of appearance (Ra) into the systemic circulation, and EGP after ingestion of a mixed meal (ingestion period indicated by striped box) before ( □ ) and after (n) ;20% weight loss induced by LAGB or RYGB. Values are median with quartiles for FGF19 and mean 6 standard error of the mean for all others. There was a significant group 3 time 3 meal interaction for all outcomes (P , 0.01). mediating the decreased desire for sweets during and between meals. In summary, weight loss induced by both LAGB and RYGB increased plasma FGF19 concentrations after mixed meal ingestion. However, weight loss induced by RYGB, but not LAGB, causes a marked increase in postprandial plasma FGF21. The increase in plasma FGF21 occurred after the peak delivery of ingested glucose to the liver, supporting the notion that hepatic glucose metabolism stimulates FGF21 production and secretion into the systemic circulation. These findings demonstrate that the alterations in FGF21 metabolism after meal consumption should be considered part of the constellation of unique postprandial metabolic adaptations that occur after RYGB, which also include higher peaks in plasma glucose and insulin, as well as glucagonlike peptide 1, peptide YY, and bile acid concentrations (35) . Additional studies are needed to determine the physiological and clinical implications of RYGB-induced alterations in FGF21 metabolism. subjects for their participation. Author Contributions: L.-A.L.S.H. was involved in sample processing and data analysis and prepared the manuscript. G.I.S. and B.M. were involved in data analysis and edited the manuscript. J.C.E. performed the surgeries and edited the manuscript. A.L.O. and B.W.P. were involved in sample processing and data analysis and edited the manuscript. S.K. obtained funding for the studies, was involved in conducting the studies, and edited the manuscript. S.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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